Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Animal and cell studiesStub

Pancragen

Short synthetic peptide (Khavinson series)

A short synthetic peptide from the Khavinson bioregulator series, described in that literature in relation to the pancreas. Published work is mostly cell and animal studies from one research group.

Reconstitution calculator

At a glance

Animal and cell studies

The published evidence is from animals and cells. Little or nothing is published from controlled trials in people.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals: Pancragen

    Laboratory and animal work. An animal result is not a result in people.

7
papers on PubMed
3
of them in people
0
randomized trials
0
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on Pancragen itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Pancragen; no amount here is a recommendation.

Pancragen: on PubMed

What PubMed held for Pancragen on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

7
papers
3
in humans
0
clinical trials
0
randomized trials
2012: 1 papers122013: 1 papers2014: 1 papers142015: 1 papers2016: 0 papers162017: 0 papers2018: 0 papers182019: 0 papers2020: 0 papers202021: 0 papers2022: 0 papers222023: 0 papers2024: 0 papers242025: 0 papers2026: 0 papers so far26
Papers per year, 2012 to 2026. The most in one year: 1.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Effects of pancragen on the differentiation of pancreatic cells during their ageing

    StudyKhavinson VKh, Durnova AO, Polyakova VO, et al. Bulletin of experimental biology and medicine, 2013. PMID 23486591

  2. Peptides tissue-specifically stimulate cell differentiation during their aging

    StudyKhavinson VKh, Linkova NS, Polyakova VO, et al. Bulletin of experimental biology and medicine, 2012. PMID 22808515

  3. Prospects of using pancragen for correction of metabolic disorders in elderly people

    StudyKorkushko OV, Khavinson VKh, Shatilo VB, et al. Bulletin of experimental biology and medicine, 2011. PMID 22448364

  4. [Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys]

    StudyGoncharova ND, Ivanova LG, Oganyan TE, et al. Advances in gerontology = Uspekhi gerontologii, 2015. PMID 28509500

  5. Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus

    StudyKhavinson VKh, Gavrisheva NA, Malinin VV, et al. Bulletin of experimental biology and medicine, 2007. PMID 18642713

  6. [Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys]

    StudyGoncharova ND, Ivanova LG, Oganian TÉ, et al. Advances in gerontology = Uspekhi gerontologii, 2014. PMID 25946840

Search used: ("Pancragen"[tiab]). Run it on PubMed

Research links

Also in Bioregulators